{
  "context": {
    "rules": [
      "Rule1: If drug X is approved for clinical trial, then drug X is approved for market.",
      "Rule2: Provided that drug Y completes phase III, if drug X passes the efficacy test, then whenever drug X passes the safety test, drug X is approved for market.",
      "Rule3: In case company A files a patent for drug X, then if it is not the case that drug X completing phase III leads to drug X receiving FDA approval, an appeal of the FDA decision is initiated.",
      "Rule4: Either company A files a patent for drug X, or company B files a patent for drug X.",
      "Rule5: Assuming company B files a patent for drug X, then if it is not the case that drug X completing phase III implies drug X receives FDA approval, an appeal of the FDA decision is initiated.",
      "Rule6: Whenever drug X receives priority status, approval of drug X is delayed.",
      "Rule7: Company A submits additional data or company B submits additional data.",
      "Rule8: Provided that drug Y is approved for clinical trial, drug X is approved for market.",
      "Rule9: In case company B submits additional data, then approval of drug X is not delayed.",
      "Rule10: Either an extension of the review period is requested, or if company A submits additional data, then approval of drug X is not delayed.",
      "Rule11: If the clinical trial yields positive results for drug X, then drug X is approved for clinical trial.",
      "Rule12: The clinical trial yields positive results for drug X or the clinical trial yields positive results for drug Y.",
      "Rule13: Assuming the research lab has collaboration with company A, then if the clinical trial yields positive results for drug Y, drug Y is approved for clinical trial.",
      "Rule14: In case company A has a partnership with the research lab, then either company A secures investment or the research lab has funding for project alpha.",
      "Rule15: Drug X meets manufacturing standards or drug Y meets manufacturing standards.",
      "Rule16: Provided that the research lab has funding for project alpha, then either drug X is approved for clinical trial or drug Y is approved for clinical trial.",
      "Rule17: Assuming drug Y meets manufacturing standards, then if drug X passes the safety test, drug X is approved for market.",
      "Rule18: If drug X completes the stability study, then drug X receives FDA approval.",
      "Rule19: Either drug X completes the stability study, or drug Y completes the stability study.",
      "Rule20: In case drug Y completes the stability study, then drug X passes quality control.",
      "Rule21: Whenever drug X passes quality control, drug Y passes quality control.",
      "Rule22: Provided that drug Y passes quality control, then if drug X passes the efficacy test, whenever drug X passes the safety test, drug X is approved for market.",
      "Rule23: If drug X completes the bioequivalence study, then drug X receives FDA approval.",
      "Rule24: Either drug X completes the bioequivalence study, or drug Y completes the bioequivalence study.",
      "Rule25: Either the agency accepts the regulatory submission, or if it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then reformulation of drug X is initiated.",
      "Rule26: If facility A has GMP certification, then facility B has GMP certification.",
      "Rule27: Provided that facility B has GMP certification, then drug X passes the toxicity test or drug X is approved for market.",
      "Rule28: Whenever company A provides clinical data, then it is not the case that approval of drug X is delayed.",
      "Rule29: If company A submits a dossier, then company A provides clinical data.",
      "Rule30: Company B submits a dossier or company B provides additional analysis.",
      "Rule31: In case company B provides additional analysis, then approval of drug X is not delayed.",
      "Rule32: Either company A requests an advisory meeting, or if company B submits a dossier, then company B provides clinical data.",
      "Rule33: Provided that company A responds to the deficiency letter, then if company A submits additional data, approval of drug X is not delayed.",
      "Rule34: Drug X completes phase III or drug Y completes phase III.",
      "Rule35: If it is not the case that drug X passes the toxicity test or drug X is approved for market, then drug X fails the toxicity test.",
      "Rule36: In case it is not the case that drug X meeting manufacturing standards leads to drug X being approved for market under safety, then drug X fails the manufacturing audit.",
      "Rule37: If it is not the case that drug Y completing the bioequivalence study leads to drug X being approved for market under efficacy and safety, then it is not the case that reformulation of drug X is initiated.",
      "Rule38: Provided that it is not the case that company A receiving a deficiency letter leads to company A responding to the deficiency letter, then company A faces regulatory sanctions.",
      "Rule39: Assuming it is not the case that drug X completing phase III implies drug X receives FDA approval, then it is not the case that an appeal of the FDA decision is initiated.",
      "Rule40: Provided that it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then the retesting requirement for drug X is waived.",
      "Rule41: If it is not the case that the negation of drug X passing the safety test implying approval leads to drug X requiring retesting, then it is not the case that the retesting requirement for drug X is waived.",
      "Rule42: In case it is not the case that the negation of the research lab having funding for project alpha leads to the research lab receiving a grant from the government agency, then the government agency terminated the grant to the research lab.",
      "Rule43: Assuming it is not the case that the negation of the research lab having funding for project alpha implies the research lab receives a grant from the government agency, then it is not the case that the government agency terminated the grant to the research lab.",
      "Rule44: Provided that it is not the case that the negation of drug X being approved for market leads to drug X qualifying for expedited review, then drug X receives priority status.",
      "Rule45: In case it is not the case that the research lab has funding for project alpha, then it is not the case that the research lab receives a grant from the government agency."
    ],
    "facts": [
      "Fact1: The research lab has collaboration with company A.",
      "Fact2: Company A has a partnership with the research lab.",
      "Fact3: Facility A has GMP certification.",
      "Fact4: Company A submits a dossier.",
      "Fact5: Company A receives a deficiency letter.",
      "Fact6: Drug X passes the safety test.",
      "Fact7: Drug X passes the efficacy test.",
      "Fact8: It is not the case that drug X passes the toxicity test.",
      "Fact9: It is not the case that drug X fails the toxicity test.",
      "Fact10: It is not the case that drug X qualifies for expedited review.",
      "Fact11: It is not the case that an extension of the review period is requested.",
      "Fact12: It is not the case that company A secures investment.",
      "Fact13: It is not the case that drug X requires retesting.",
      "Fact14: It is not the case that drug X fails the manufacturing audit.",
      "Fact15: It is not the case that the agency accepts the regulatory submission.",
      "Fact16: It is not the case that company B provides clinical data.",
      "Fact17: It is not the case that company A requests an advisory meeting.",
      "Fact18: It is not the case that company A faces regulatory sanctions.",
      "Fact19: It is not the case that drug X receives FDA approval."
    ]
  },
  "question": "Drug X is approved for market."
}